Biohaven Ltd. (BHVN) 10-Year Financial Performance & Capital Metrics

BHVN • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutBiohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.Show more

Revenue $0
EBITDA -$877M -104.4%
Net Income -$846M -107.4%
EPS (Diluted) -9.28 -62.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -198.83% -135.5%
ROIC -232.38% -105.3%
Debt/Equity 0.09 +19.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 28.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.01%

EPS CAGR

10Y-

5Y-

3Y-

TTM18.72%

ROCE

10Y Avg-153.88%

5Y Avg-150.2%

3Y Avg-148.82%

Latest-192.69%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	479.12M	114.51M	218.9M	567.93M	436.05M	885.11M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	134.45M	16.05M	37.41M	130.86M	62.77M	89.24M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	344.67M	98.46M	181.49M	437.07M	373.28M	795.87M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-479.12M	-114.51M	-218.9M	-567.93M	-436.05M	-885.11M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.76%	-0.91%	-1.59%	0.23%	-1.03%
EBITDA+	-478.95M	-114.43M	-217.51M	-566.55M	-429.14M	-877.26M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.76%	-0.9%	-1.6%	0.24%	-1.04%
D&A (Non-Cash Add-back)	171.86K	72K	1.39M	1.39M	6.91M	7.86M
EBIT	-541.1M	-114.51M	-218.9M	-567.93M	-436.05M	-885.11M
Net Interest Income+	0	0	0	0	17.73M	21.33M
Interest Income	0	0	0	0	17.73M	21.33M
Interest Expense	-12.71M	0	0	0	0	0
Other Income/Expense	-49.26M	-4.16M	6.47M	-1.91M	26.5M	39.42M
Pretax Income+	-528.39M	-118.67M	-212.43M	-569.84M	-409.55M	-845.69M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	419K	0	1.37M	438K	-1.38M	735K
Effective Tax Rate %	1%	1%	1.01%	1%	1%	1%
Net Income+	-528.8M	-118.67M	-213.8M	-570.28M	-408.17M	-846.42M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	0.78%	-0.8%	-1.67%	0.28%	-1.07%
Net Income (Continuing)	-528.8M	-118.67M	-213.8M	-570.28M	-408.17M	-846.42M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	60M	60M	0	0	0
EPS (Diluted)+	-10.91	-3.31	-5.97	-12.75	-5.73	-9.28
EPS Growth %	-	0.7%	-0.8%	-1.14%	0.55%	-0.62%
EPS (Basic)	-10.91	-3.31	-5.97	-12.75	-5.73	-9.28
Diluted Shares Outstanding	48.49M	35.82M	35.82M	44.74M	71.2M	91.23M
Basic Shares Outstanding	48.49M	35.82M	35.82M	44.74M	71.2M	91.23M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	328.28M	89.76M	94.82M	586.97M	442.45M	538.47M
Cash & Short-Term Investments	316.73M	82.51M	76.06M	465.34M	381.82M	485.99M
Cash Only	316.73M	82.51M	76.06M	204.88M	248.4M	99.13M
Short-Term Investments	0	0	0	260.46M	133.42M	386.86M
Accounts Receivable	0	0	0	46.14M	13.25M	2.6M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	11.55M	10K	12.03M	54.54M	12.13M	508K
Total Non-Current Assets+	15.98M	21.74M	47.24M	74.81M	70.77M	76.64M
Property, Plant & Equipment	8.15M	13.56M	17.68M	52.44M	48.58M	53.71M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	1.39M	1.39M	1.39M	1.39M
Intangible Assets	0	0	18.95M	18.4M	18.4M	18.4M
Long-Term Investments	0	7.18M	6M	0	0	0
Other Non-Current Assets	7.83M	1.01M	3.22M	2.58M	2.4M	3.13M
Total Assets+	344.26M	111.5M	142.06M	661.78M	513.21M	615.11M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.68%	0.27%	3.66%	-0.22%	0.2%
Total Current Liabilities+	66.17M	29.88M	41.94M	90.02M	55.42M	154.23M
Accounts Payable	14.07M	2.76M	4.78M	10.7M	15.58M	18.03M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	52.1M	7.55M	0	14.6M	0	84.71M
Current Ratio	4.96x	3.00x	2.26x	6.52x	7.98x	3.49x
Quick Ratio	4.96x	3.00x	2.26x	6.52x	7.98x	3.49x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	285.51M	4.84M	5.43M	32.99M	29.81M	37.45M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	2.93M	2.8M	30.58M	27.57M	32.78M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	285.51M	1.91M	2.64M	2.41M	2.25M	4.66M
Total Liabilities	351.69M	34.72M	47.37M	123.01M	85.24M	191.67M
Total Debt+	0	3.6M	3.24M	33.6M	30.88M	36.58M
Net Debt	-316.73M	-78.9M	-72.82M	-171.28M	-217.53M	-62.55M
Debt / Equity	-	0.05x	0.03x	0.06x	0.07x	0.09x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	-7.42M	76.78M	94.69M	538.77M	427.98M	423.44M
Equity Growth %	-	11.34%	0.23%	4.69%	-0.21%	-0.01%
Book Value per Share	-0.15	2.14	2.64	12.04	6.01	4.64
Total Shareholders' Equity	-7.42M	16.78M	34.69M	538.77M	427.98M	423.44M
Common Stock	881.43M	16.78M	34.69M	615.74M	887.53M	1.66B
Retained Earnings	-972.37M	0	0	-91.12M	-499.29M	-1.35B
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	284K	-65K	79K
Minority Interest	0	60M	60M	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-377.33M	-75.96M	-145.84M	-297.69M	-331.73M	-582.45M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	0.8%	-0.92%	-1.04%	-0.11%	-0.76%
Net Income	-528.8M	-118.67M	-213.8M	-570.28M	-408.17M	-846.42M
Depreciation & Amortization	0	72K	1.39M	1.39M	6.91M	7.86M
Stock-Based Compensation	54.97M	29.5M	65.64M	193.56M	28.79M	71.96M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	93.18M	4.16M	-740K	106.25M	16.13M	167.34M
Working Capital Changes	3.32M	8.98M	1.66M	-28.6M	24.61M	16.81M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	3.32M	222K	1.02M	5.93M	4.87M	710K
Cash from Investing+	-3.78M	-2.7M	944K	-304.79M	129.83M	-244.97M
Capital Expenditures	-2.53M	-2.7M	-938K	-41.07M	-3.05M	-4.05M
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-1.25M	0	0	0	0	0
Cash from Financing+	434.59M	152.24M	138.45M	767.6M	211.91M	677.77M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	434.59M	152.24M	138.45M	34.66M	-31.32M	2.26M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-379.87M	-78.65M	-146.78M	-338.76M	-334.77M	-586.5M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	0.79%	-0.87%	-1.31%	0.01%	-0.75%
FCF per Share	-7.83	-2.20	-4.10	-7.57	-4.70	-6.43
FCF Conversion (FCF/Net Income)	0.71x	0.64x	0.68x	0.52x	0.81x	0.69x
Interest Paid	0	0	107K	0	0	0
Taxes Paid	0	2.76M	16.59M	38.16M	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-342.19%	-249.37%	-180.05%	-84.44%	-198.83%
Return on Invested Capital (ROIC)	-	-	-1662.62%	-218.79%	-113.17%	-232.38%
Debt / Equity	-	0.05x	0.03x	0.06x	0.07x	0.09x
FCF Conversion	0.71x	0.64x	0.68x	0.52x	0.81x	0.69x

Frequently Asked Questions

Growth & Financials

Biohaven Ltd. (BHVN) grew revenue by 0.0% over the past year. Growth has been modest.

Biohaven Ltd. (BHVN) reported a net loss of $780.1M for fiscal year 2024.

Dividend & Returns

Biohaven Ltd. (BHVN) has a return on equity (ROE) of -198.8%. Negative ROE indicates the company is unprofitable.

Biohaven Ltd. (BHVN) had negative free cash flow of $650.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener